Next earnings date: 4 Aug 2025
ESSA Pharma Inc. – NASDAQ:EPIX
ESSA Pharma stock price today
$1.91
+0.15
+9.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
ESSA Pharma stock price monthly change
-67.47%
month
ESSA Pharma stock price quarterly change
-67.47%
quarter
ESSA Pharma stock price yearly change
-74.96%
year
ESSA Pharma key metrics
Market Cap | 71.43M |
Enterprise value | 77.65M |
P/E | -3.84 |
EV/Sales | N/A |
EV/EBITDA | -2.37 |
Price/Sales | N/A |
Price/Book | 0.79 |
PEG ratio | -0.23 |
EPS | -0.65 |
Revenue | N/A |
EBITDA | -30.25M |
Income | -28.83M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeESSA Pharma stock price history
ESSA Pharma stock forecast
ESSA Pharma financial statements
Average Price Target
$11.33
Potential upside: 493.36%
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 0 | -7.06M | |
|---|---|---|---|
| Jun 2023 | 0 | -7.29M | |
| Sep 2023 | 0 | -5.48M | |
| Mar 2024 | 0 | -8.98M |
| 2024-08-05 | -0.26 | -0.16 |
|---|
| Mar 2023 | 158504000 | 2.16M | 1.37% |
|---|---|---|---|
| Jun 2023 | 153650198 | 3.40M | 2.22% |
| Sep 2023 | 149122131 | 3.49M | 2.34% |
| Mar 2024 | 137896175 | 4.42M | 3.21% |
| Mar 2023 | -6.97M | 86.26K | -34.63K |
|---|---|---|---|
| Jun 2023 | -3.32M | -2.47M | -35.52K |
| Sep 2023 | -4.48M | -264.64K | -13.64K |
| Mar 2024 | -6.88M | 62.86M | 647.81K |
ESSA Pharma alternative data
| Aug 2023 | 50 |
|---|---|
| Sep 2023 | 50 |
| Oct 2023 | 50 |
| Nov 2023 | 50 |
| Dec 2023 | 50 |
| Jan 2024 | 50 |
| Feb 2024 | 50 |
| Apr 2024 | 50 |
| May 2024 | 50 |
| Jun 2024 | 50 |
| Jul 2024 | 50 |
ESSA Pharma other data
1.57%
-74.13%
of EPIX is owned by hedge funds
14
-26
690.99K
-32.64M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 32736 | 272840 |
| Nov 2023 | 99730 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BERGER FRANKLIN M director | Common Shares | 23,259 | $5.73 | $133,274 | ||
Purchase | BERGER FRANKLIN M director | Common Stock | 16,471 | $5.99 | $98,661 | ||
Purchase | BERGER FRANKLIN M director | Common Stock | 60,000 | $5.35 | $321,000 | ||
Purchase | PARKINSON DAVID ROSS officer: Chief Ex.. | Common Shares | 3,067 | $2.6 | $7,974 | ||
Purchase | WOOD DAVID S. officer: Chief Financial Officer | Common Shares | 8,302 | $2.6 | $21,585 | ||
Purchase | PARKINSON DAVID ROSS director, officer.. | Common Shares | 21,367 | $2.39 | $51,067 | ||
Sale | BERGER FRANKLIN M director | Common Shares | 34,334 | $2.42 | $83,088 | ||
Sale | BERGER FRANKLIN M director | Common Shares | 37,889 | $2.41 | $91,312 | ||
Sale | BERGER FRANKLIN M director | Common Shares | 43,617 | $2.53 | $110,351 | ||
Sale | BERGER FRANKLIN M director | Common Shares | 50,000 | $2.67 | $133,500 |
| Patent |
|---|
Application Filling date: 28 Apr 2022 Issue date: 18 Aug 2022 |
Application PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF Filling date: 27 Mar 2020 Issue date: 14 Jul 2022 |
Application PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF Filling date: 27 Mar 2020 Issue date: 30 Jun 2022 |
Application PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF Filling date: 16 Sep 2021 Issue date: 7 Apr 2022 |
Application Filling date: 15 Nov 2021 Issue date: 10 Mar 2022 |
Grant Filling date: 9 Jun 2021 Issue date: 8 Feb 2022 |
Application Filling date: 9 Jun 2021 Issue date: 28 Oct 2021 |
Application Filling date: 16 Apr 2021 Issue date: 21 Oct 2021 |
Grant Filling date: 20 Apr 2020 Issue date: 13 Jul 2021 |
Application Filling date: 24 May 2019 Issue date: 1 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q2 2008 24 Sep 2008 | Q2 2008 Earnings Call Transcript |
| Q4 2007 25 Feb 2008 | Q4 2007 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. David Ross Parkinson (1950) Pres, Chief Executive Officer & Director | $788,600 |
Mr. Peter A. Virsik M.B.A., M.S. (1971) Executive Vice President & Chief Operating Officer | $615,590 |
ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance
Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data
ESSA Pharma: One Asset, One Program Company With Little Data
ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer
ESSA Pharma Inc.: Selling For Under Cash Value
ESSA Pharma: Why I Remain Bullish
-
What's the price of ESSA Pharma stock today?
One share of ESSA Pharma stock can currently be purchased for approximately $1.91.
-
When is ESSA Pharma's next earnings date?
ESSA Pharma Inc. is estimated to report earnings on Monday, 4 Aug 2025.
-
Does ESSA Pharma pay dividends?
No, ESSA Pharma does not pay dividends.
-
How much money does ESSA Pharma make?
ESSA Pharma has a market capitalization of 71.43M.
-
What is ESSA Pharma's stock symbol?
ESSA Pharma Inc. is traded on the NASDAQ under the ticker symbol "EPIX".
-
What is ESSA Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ESSA Pharma?
Shares of ESSA Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ESSA Pharma's key executives?
ESSA Pharma's management team includes the following people:
- Dr. David Ross Parkinson Pres, Chief Executive Officer & Director(age: 75, pay: $788,600)
- Mr. Peter A. Virsik M.B.A., M.S. Executive Vice President & Chief Operating Officer(age: 54, pay: $615,590)
-
How many employees does ESSA Pharma have?
As Jul 2024, ESSA Pharma employs 50 workers.
-
When ESSA Pharma went public?
ESSA Pharma Inc. is publicly traded company for more then 10 years since IPO on 13 Mar 2015.
-
What is ESSA Pharma's official website?
The official website for ESSA Pharma is essapharma.com.
-
Where are ESSA Pharma's headquarters?
ESSA Pharma is headquartered at 999 West Broadway, Vancouver, BC.
-
How can i contact ESSA Pharma?
ESSA Pharma's mailing address is 999 West Broadway, Vancouver, BC and company can be reached via phone at +1 778 331 0962.
-
What is ESSA Pharma stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for ESSA Pharma in the last 12 months, the avarage price target is $11.33. The average price target represents a 493.36% change from the last price of $1.91.
ESSA Pharma company profile:
ESSA Pharma Inc.
essapharma.comExchange:
NASDAQ
Full time employees:
50
Industry:
Biotechnology
Sector:
Healthcare
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
999 West Broadway
Vancouver, BC V5Z 1K5
Vancouver, BC V5Z 1K5
CIK: 0001633932
ISIN: CA29668H7085
CUSIP: 29668H708
